Stock listing
NASDAQ:GANX Gain Therapeutics, Inc. Stock
Home listing (NASDAQ) of Gain Therapeutics, Inc.
Follow Gain Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:GANX
$0.999 USD -0.111 (-10.0%)
Close on Nov 20, 2026
- Day range
- $0.970 – $1.099 USDNov 20, 2026
- Volume
- 585,937 sharesNov 20, 2026
- Market cap
- $44.50M USDAt the close on Nov 20, 2026 · price × 44.53M shares outstanding
- 52-week range
- $0.940 – $4.340 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $782,717 USDMedian day 383,023 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GANX · Home | $0.999 USD | -0.111 (-10.0%) | 585,937 | $1.020 | $1.099 | $0.970 | $1.110 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GANX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.999 | -0.111 | -10.0% | $1.020 | $1.099 | $0.970 | 585,937 | |
| $1.110 | -0.070 | -5.9% | $1.230 | $1.240 | $1.080 | 1,156,199 | |
| $1.180 | +0.240 | +25.5% | $0.980 | $1.300 | $0.970 | 4,310,888 | |
| $0.940 | -0.100 | -9.6% | $1.010 | $1.077 | $0.940 | 591,261 | |
| $1.040 | -0.040 | -3.7% | $1.120 | $1.135 | $1.010 | 328,879 | |
| $1.080 | -0.030 | -2.7% | $1.060 | $1.140 | $1.010 | 300,382 | |
| $1.110 | +0.030 | +2.8% | $1.120 | $1.160 | $1.070 | 292,767 | |
| $1.080 | -0.010 | -0.9% | $1.100 | $1.180 | $1.050 | 411,687 | |
| $1.090 | +0.060 | +5.8% | $1.020 | $1.115 | $1.000 | 309,671 | |
| $1.030 | +0.070 | +7.2% | $0.970 | $1.030 | $0.960 | 328,332 | |
| $0.960 | -0.150 | -13.5% | $1.100 | $1.121 | $0.940 | 849,002 | |
| $1.110 | -0.040 | -3.5% | $1.180 | $1.210 | $1.100 | 228,583 | |
| $1.150 | +0.020 | +1.8% | $1.130 | $1.190 | $1.130 | 193,725 | |
| $1.130 | 0.000 | 0.0% | $1.150 | $1.200 | $1.120 | 268,674 | |
| $1.130 | -0.060 | -5.0% | $1.180 | $1.195 | $1.110 | 364,700 | |
| $1.190 | -0.005 | -0.4% | $1.200 | $1.250 | $1.170 | 177,200 | |
| $1.195 | +0.025 | +2.1% | $1.160 | $1.200 | $1.160 | 400,425 | |
| $1.170 | +0.020 | +1.7% | $1.160 | $1.210 | $1.140 | 508,340 | |
| $1.150 | -0.110 | -8.7% | $1.280 | $1.280 | $1.140 | 811,024 | |
| $1.260 | -0.030 | -2.3% | $1.330 | $1.343 | $1.220 | 645,033 | |
| $1.290 | +0.100 | +8.4% | $1.180 | $1.330 | $1.160 | 2,751,162 | |
| $1.190 | 0.000 | 0.0% | $1.200 | $1.230 | $1.150 | 609,772 | |
| $1.190 | -0.060 | -4.8% | $1.230 | $1.295 | $1.170 | 517,004 | |
| $1.250 | -0.010 | -0.8% | $1.260 | $1.290 | $1.210 | 532,167 | |
| $1.260 | -0.070 | -5.3% | $1.320 | $1.377 | $1.235 | 467,379 | |
| $1.330 | +0.010 | +0.8% | $1.320 | $1.410 | $1.310 | 510,815 | |
| $1.320 | -0.090 | -6.4% | $1.370 | $1.420 | $1.295 | 851,301 | |
| $1.410 | -0.160 | -10.2% | $1.580 | $1.580 | $1.400 | 799,935 | |
| $1.570 | -0.070 | -4.3% | $1.650 | $1.650 | $1.565 | 319,798 | |
| $1.640 | +0.025 | +1.5% | $1.610 | $1.660 | $1.610 | 328,689 | |
| $1.615 | -0.055 | -3.3% | $1.660 | $1.675 | $1.610 | 361,863 | |
| $1.670 | 0.000 | 0.0% | $1.660 | $1.690 | $1.640 | 373,931 | |
| $1.670 | -0.020 | -1.2% | $1.700 | $1.750 | $1.655 | 646,562 | |
| $1.690 | -0.020 | -1.2% | $1.750 | $1.770 | $1.690 | 351,043 | |
| $1.710 | -0.010 | -0.6% | $1.750 | $1.780 | $1.700 | 386,093 | |
| $1.720 | -0.010 | -0.6% | $1.725 | $1.773 | $1.670 | 497,407 | |
| $1.730 | +0.050 | +3.0% | $1.700 | $1.840 | $1.690 | 787,967 | |
| $1.680 | -0.090 | -5.1% | $1.750 | $1.760 | $1.600 | 1,289,905 | |
| $1.770 | -0.010 | -0.6% | $1.750 | $1.820 | $1.720 | 548,024 | |
| $1.780 | -0.060 | -3.3% | $1.850 | $1.883 | $1.775 | 383,023 | |
| $1.840 | 0.000 | 0.0% | $1.840 | $1.855 | $1.790 | 407,684 | |
| $1.840 | -0.110 | -5.6% | $1.910 | $1.973 | $1.830 | 292,877 | |
| $1.950 | +0.110 | +6.0% | $1.850 | $1.960 | $1.825 | 692,699 | |
| $1.840 | +0.080 | +4.5% | $1.800 | $1.850 | $1.780 | 335,860 | |
| $1.760 | -0.020 | -1.1% | $1.790 | $1.805 | $1.750 | 375,549 | |
| $1.780 | +0.060 | +3.5% | $1.770 | $1.785 | $1.735 | 341,535 | |
| $1.720 | +0.010 | +0.6% | $1.730 | $1.790 | $1.700 | 265,926 | |
| $1.710 | -0.030 | -1.7% | $1.740 | $1.740 | $1.690 | 215,693 | |
| $1.740 | -0.010 | -0.6% | $1.760 | $1.800 | $1.730 | 360,117 | |
| $1.750 | +0.040 | +2.3% | $1.748 | $1.780 | $1.720 | 223,559 | |
| $1.710 | -0.010 | -0.6% | $1.720 | $1.740 | $1.690 | 505,647 | |
| $1.720 | -0.110 | -6.0% | $1.810 | $1.830 | $1.720 | 513,385 | |
| $1.830 | +0.030 | +1.7% | $1.800 | $1.850 | $1.770 | 292,335 | |
| $1.800 | -0.020 | -1.1% | $1.810 | $1.830 | $1.785 | 205,350 | |
| $1.820 | +0.030 | +1.7% | $1.800 | $1.825 | $1.770 | 391,412 | |
| $1.790 | +0.020 | +1.1% | $1.780 | $1.846 | $1.750 | 367,689 | |
| $1.770 | -0.030 | -1.7% | $1.830 | $1.830 | $1.770 | 197,909 | |
| $1.800 | +0.030 | +1.7% | $1.770 | $1.840 | $1.760 | 259,893 | |
| $1.770 | -0.080 | -4.3% | $1.840 | $1.855 | $1.760 | 312,529 | |
| $1.850 | +0.040 | +2.2% | $1.850 | $1.900 | $1.795 | 416,109 | |
| $1.810 | -0.095 | -5.0% | $1.910 | $1.920 | $1.800 | 723,423 | |
| $1.905 | -0.095 | -4.7% | $2.000 | $2.050 | $1.900 | 383,518 | |
| $2.000 | -0.005 | -0.2% | $2.010 | $2.030 | $1.930 | 315,900 | |
| $2.005 | +0.025 | +1.3% | $2.000 | $2.045 | $1.980 | 277,476 | |
| $1.980 | -0.090 | -4.3% | $2.030 | $2.035 | $1.950 | 382,528 |
- Ticker
- NASDAQ:GANX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 27 slides
Latest news
Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
Nov 17, 2026
Closed $1.11 (-5.9%) on Nov 18, 2026
Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Nov 10, 2026
Closed $1.08 (-0.9%) on Nov 10, 2026
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
Nov 5, 2026
Closed $0.96 (-13.5%) on Nov 5, 2026
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
Oct 8, 2026
Closed $1.62 (-3.3%) on Oct 8, 2026
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
Oct 1, 2026
Closed $1.72 (-0.6%) on Oct 1, 2026
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
Sep 29, 2026
Closed $1.73 (+3.0%) on Sep 30, 2026
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
Sep 17, 2026
Closed $1.78 (+3.5%) on Sep 17, 2026
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
Aug 25, 2026
Closed $1.91 (-4.7%) on Aug 25, 2026
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
Aug 11, 2026
Closed $2.06 (+16.4%) on Aug 11, 2026
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Jul 16, 2026
Closed $1.66 (-1.2%) on Jul 16, 2026
Gain Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 118 in all · newest Nov 17, 2026 · oldest 2021
- Decks
- 33 decks · latest October 2026
Where Gain Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GANX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:GANX | BOATS | United States | USD |
Valuation
Price/book 4.4× against a median of 5.1×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $33.11M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.60
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Gain Therapeutics, Inc. · NASDAQ:GANX | US$44.50M | US$33.11M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.60 |
| MegaPro Biomedical Co., Ltd. · TPEX:6827 | US$45.96M | US$43.30M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| SunBio, Inc. · KRX:067370 | US$45.55M | US$42.68M | 14.2× | 4.6× | 8.9× | 2.0× | 34.6% | 0.0× | n/a |
| Apollomics Inc. · NASDAQ:APLM | US$45.28M | US$42.65M | n/a | 5.0× | n/a | n/a | −128.7% | n/a | 1.02 |
| Zelluna ASA · OSL:ZLNA | US$45.14M | US$38.93M | n/a | n/a | n/a | 5.1× | n/a | 0.0× | n/a |
| Oncoinvent ASA · OSL:ONCIN | US$44.87M | US$33.89M | n/a | 14.3× | n/a | 5.4× | −673.1% | 0.0× | n/a |
| ImageneBio, Inc. · NASDAQ:IMA | US$44.50M | −US$80.79M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.52 |
| Annovis Bio, Inc. · NYSE:ANVS | US$44.12M | US$41.30M | n/a | n/a | n/a | n/a | n/a | n/a | 2.53 |
| Arch Biopartners, Inc. · TSXV:ARCH | US$44.06M | US$44.06M | n/a | n/a | n/a | n/a | n/a | n/a | 0.94 |
| Spero Therapeutics, Inc. · NASDAQ:SPRO | US$43.23M | −US$63.10M | n/a | −1.5× | n/a | 55.4× | −71.0% | 2.0× | 1.68 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Median of the others | US$44.68M | US$40.11M | 14.2× | 4.8× | 8.9× | 5.1× | −99.9% | 0.0× | 1.02 |
Forecasts
4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.20 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.41 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Gene Mack | Chief Executive Officer |
| Apaar Jammu | Director, Investor Relations and Public Relations |
| Investors:Gain Therapeutics | Inc. Apaar Jammu Director, Investor Relations and Public |
Board
| Director | Role |
|---|---|
| Khalid Islam | Chairman |
| Claude Nicaise | Independent Member |
| Dov Goldstein | Independent Member |
| Gene Mack | Chief Executive Officer |
| Gwen Melincoff | Independent Member |
| Hans Peter Hasler | Independent Member |
| Jeffrey Riley | Independent Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +2.8% |
| Q2 2026 | Aug 11, 2026 · After close | +2.9% |
| Q1 2026 | May 11, 2026 · After close | −1.1% |
| Q4 2025 | Mar 19, 2026 | 0.0% |
| Q3 2025 | Nov 12, 2025 · After close | +1.4% |
| Q2 2025 | Aug 12, 2025 · After close | +1.3% |
| Q1 2025 | May 14, 2025 · After close | −2.7% |
| Q4 2024 | Mar 24, 2025 · Before open | −0.8% |
| Q3 2024 | Nov 14, 2024 · After close | +5.7% |
| Q2 2024 | Aug 8, 2024 · After close | +1.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | +12.0% |
| Q4 2023 | Mar 26, 2024 · Before open | +4.1% |
| Q3 2023 | Nov 14, 2023 · After close | +4.3% |
| Q2 2023 | Aug 10, 2023 · After close | −0.8% |
| Q1 2023 | May 12, 2023 · Before open | +0.4% |
| Q4 2022 | Mar 23, 2023 · After close | +1.2% |
| Q3 2022 | Nov 10, 2022 · After close | +1.3% |
| Q2 2022 | Aug 8, 2022 · Before open | +5.0% |
| Q1 2022 | May 16, 2022 · After close | 0.0% |
| Q4 2021 | Mar 25, 2022 · After close | −5.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 27 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 27 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 26 slides | August 2026 |
| Investor Presentation (July 2026) | Investor deck | 27 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 25 slides | June 2026 |
| Investor Presentation (May 2026) | Investor deck | 24 slides | May 2026 |
| Investor Presentation (March 2026) | Investor deck | 25 slides | March 2026 |
| Investor Presentation (March 2026) | Investor deck | 24 slides | March 2026 |
| Investor Presentation (February 2026) | Investor deck | 19 slides | Feb 3, 2026 |
| Investor Presentation (February 2026) | Investor deck | 19 slides | February 2026 |
All 33 decks
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock and warrants to purchase common stock Announced: about US$7M · US$3.11 a share · 1 warrant at US$1.65 for 60 months · Newbridge Securities Corporation Dealers: Newbridge Securities Corporation (lead) Use of proceeds: Clinical and nonclinical development of lead candidate GT-02287 for neurodegenerative diseases including GBA1 Parkinson's, and general corporate purposes | Jul 16, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$11.00 a share on Mar 17, 2021.
- Price
- US$11.00 a share
- Shares offered
- 3,636,364 shares of common stock
- Offering size
- US$40 million
- Underwriters' option
- Up to 545,454 more shares
- Listing
- GANX on the Nasdaq Global Market
- Underwriters
- BTIG, Oppenheimer & Co., National Securities Corporation · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 16, 2020 |
| Filed publicly | Feb 19, 2021 |
| Amended twice | Newest Mar 15, 2021 |
| Shares registered with an exchange | Mar 17, 2021 |
| Declared effective by the SEC | Mar 17, 2021 |
| Final prospectus, with the price | Mar 22, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 22, 2021 |
| EFFECT · Notice that a registration is effective | Mar 17, 2021 |
| CERT · Exchange's certificate of listing | Mar 17, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 17, 2021 |
| CORRESP · Letter to the SEC | Mar 16, 2021 |
| UPLOAD · Letter from the SEC | Mar 16, 2021 |
| CORRESP · Letter to the SEC | Mar 15, 2021 |
| CORRESP · Letter to the SEC | Mar 15, 2021 |
| CORRESP · Letter to the SEC | Mar 15, 2021 |
| S-1/A · Registration statement, amended | Mar 15, 2021 |
All 25 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Mar 12, 2021 |
| CORRESP · Letter to the SEC | Mar 10, 2021 |
| S-1/A · Registration statement, amended | Mar 10, 2021 |
| UPLOAD · Letter from the SEC | Feb 23, 2021 |
| CORRESP · Letter to the SEC | Feb 19, 2021 |
| S-1 · Registration statement | Feb 19, 2021 |
| UPLOAD · Letter from the SEC | Feb 3, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jan 29, 2021 |
| DRS/A · Draft registration statement, amended | Jan 29, 2021 |
| UPLOAD · Letter from the SEC | Jan 19, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jan 8, 2021 |
| DRS/A · Draft registration statement, amended | Jan 8, 2021 |
| UPLOAD · Letter from the SEC | Dec 14, 2020 |
| DRSLTR · Letter to the SEC with a draft | Nov 16, 2020 |
| DRS · Draft registration statement | Nov 16, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 22, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 55.2K | 140.1K | 165.0K | 28.9K | 41.3K | 20.6K |
| Cost of revenue | 94.0K | 84.1K | 80.4K | 8.24M | 7.16M | 2.26M | ||
| Gross profit | -94.0K | -84.1K | 55.2K | 140.1K | 165.0K | 28.9K | 41.3K | 20.6K |
| Research and development | 10.2M | 10.8M | 11.5M | 8.38M | 7.16M | 2.26M | 1.59M | 826.9K |
| Selling, general and administrative | 8.50M | 9.56M | 10.8M | 9.54M | 6.83M | 1.25M | 555.2K | 222.0K |
| Operating income | -18.7M | -20.4M | -22.3M | -17.8M | -13.8M | -3.48M | -2.10M | -1.03M |
| Depreciation and amortization | 94.0K | 84.1K | 83.6K | 64.2K | 15.5K | 9.59K | 2.57K | 741 |
| EBITDA | -18.6M | -20.3M | -22.2M | -17.7M | -13.8M | -3.47M | -2.10M | -1.03M |
| Interest expense | 247.4K | 0 | 189.3K | 20.5K | 52.5K | |||
| Income before tax | -19.3M | -19.9M | -22.2M | -17.5M | -13.9M | -3.57M | -2.19M | -1.10M |
| Income tax | 861.1K | 536.8K | 79.3K | 93.0K | 4.01K | 5.39K | 7.11K | 9.78K |
| Net income | -20.2M | -20.4M | -22.3M | -17.6M | -13.9M | -3.58M | -2.19M | -1.11M |
| Earnings per share, basic | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 | -1.33 | -0.26 | -0.19 |
| Earnings per share, diluted | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 | -1.33 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 20.8M | 10.4M | 11.8M | 7.31M | 36.9M | 7.49M | 303.3K | 400.7K |
| Short-term investments | 0 | 5.00M | 12.8M | 0 | ||||
| Receivables | 802.7K | 765.8K | 242.6K | 103.9K | 195.4K | 8.55K | 44.9K | 41.8K |
| Inventory | 1.36M | 31.5K | ||||||
| Current assets | 22.2M | 11.6M | 17.8M | 21.1M | 37.7M | 8.99M | 398.0K | 494.6K |
| Property, plant and equipment | 74.9K | 103.6K | 126.0K | 144.4K | 106.0K | 29.6K | 219.3K | 305.8K |
| Total assets | 22.8M | 12.1M | 18.6M | 24.1M | 39.0M | 9.60M | 660.3K | 811.6K |
| Accounts payable | 825.0K | 946.3K | 1.32M | 1.63M | 560.5K | 961.5K | 154.4K | 149.3K |
| Current liabilities | 3.35M | 3.91M | 4.95M | 4.13M | 2.55M | 2.11M | 879.1K | 530.8K |
| Long-term debt | 300.1K | 328.3K | 449.1K | 495.3K | 590.5K | 715.7K | ||
| Total debt | 401.0K | 438.5K | 567.9K | 603.4K | 694.3K | 738.3K | 200.9K | 1.31M |
| Total liabilities | 4.25M | 4.78M | 6.03M | 5.22M | 4.17M | 3.40M | 1.11M | 1.76M |
| Shareholders' equity | 18.6M | 7.34M | 12.6M | 18.9M | 34.8M | 6.20M | -449.9K | -950.9K |
| Shares outstanding | 42.1M | 27.1M | 16.2M | 11.9M | 11.9M | 3.54M | 8.37M | 5.86M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -18.5M | -18.9M | -18.9M | -14.7M | -12.4M | -3.24M | -1.87M | -744.5K |
| Capital spending | -2 | -22.5K | -15.4K | -119.0K | -94.2K | -20.8K | -13.7K | -7.99K |
| Free cash flow | -18.5M | -18.9M | -18.9M | -14.8M | -12.5M | -3.26M | -1.88M | -752.5K |
| Cash from investing | 4.98M | 10.2M | -14.8M | -94.2K | -20.8K | -13.7K | -7.99K | |
| Cash from financing | 28.4M | 13.0M | 12.6M | -78.8K | 41.8M | 10.5M | 1.75M | 983.8K |
| Change in cash | 10.5M | -1.41M | 4.49M | -29.6M | 29.4M | 7.19M | -97.2K | 237.9K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 17, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 8-K · Current report | Sep 28, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 16, 2026 | Current report | SEC |
| 8-K · Current report | Jun 29, 2026 | Current report | SEC |
| 8-K · Current report | Jun 25, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 8-K · Current report | Mar 18, 2026 | Current report | SEC |
| 8-K · Current report | Feb 3, 2026 | Current report | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Dec 3, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 28, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 28, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| S-3/A · Registration statement, amended | Nov 7, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| 8-K · Current report | Oct 9, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 6, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 424B5 · Prospectus | Jul 17, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 17, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 15, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2025 | Meeting outcome | SEC |
| UPLOAD · Letter from the SEC | Jun 4, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 28, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 10, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 6, 2025 | Current report | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 7, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 23, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 8-K · Current report | Oct 21, 2024 | Current report | SEC |
| 8-K · Current report | Oct 8, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Sep 19, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Sep 6, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 6, 2024 | Material contract | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jul 12, 2024 | Current report | SEC |
| 8-K · Current report | Jul 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| FWP · Free writing prospectus | Jul 1, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 28, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2024 | Meeting outcome | SEC |
| 424B5 · Prospectus | Jun 17, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 14, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 13, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 8, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 26, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 22, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 31, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jan 2, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 2, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 22, 2023 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Dec 22, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 21, 2023 | Other filings | SEC |
| S-1 · Registration statement | Dec 19, 2023 | Offer document | SEC |
| 4 · Change in ownership | Dec 14, 2023 | Insider trade | SEC |
| 424B5 · Prospectus | Nov 24, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 22, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Nov 20, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 17, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2023 | Meeting outcome | SEC |
| S-8 · Registration statement for employee plans | May 26, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Apr 12, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 12, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 12, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Mar 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2023 | Insider trade | SEC |
| 10-K · Annual report | Mar 23, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2023 | Results | SEC |
| 3 · Initial statement of ownership | Dec 21, 2022 | Insider trade | SEC |
| 8-K · Current report | Dec 16, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2022 | Results | SEC |
| 4 · Change in ownership | Sep 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2022 | Insider trade | SEC |
| 8-K · Current report | Sep 20, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2022 | Results | SEC |
| 4 · Change in ownership | Jul 19, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2022 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jul 15, 2022 | Offer document | SEC |
| 8-K · Current report | Jun 17, 2022 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Jun 2, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 31, 2022 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2022 | Insider trade | SEC |
| S-3/A · Registration statement, amended | May 23, 2022 | Offer document | SEC |
| 4/A · Change in ownership, amended | May 23, 2022 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 20, 2022 | Other filings | SEC |
| 4 · Change in ownership | May 19, 2022 | Insider trade | SEC |
| S-3 · Registration statement | May 18, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | May 16, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 16, 2022 | Results | SEC |
| DEF 14A · Proxy statement | May 13, 2022 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | May 2, 2022 | Annual report | SEC |
| 4/A · Change in ownership, amended | Apr 21, 2022 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Apr 21, 2022 | Insider trade | SEC |
| 10-K · Annual report | Mar 25, 2022 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2022 | Results | SEC |
| 4 · Change in ownership | Dec 28, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 28, 2021 | Insider trade | SEC |
| 8-K · Current report | Dec 28, 2021 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 12, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2021 | Results | SEC |
| 8-K · Current report | Oct 20, 2021 | Management or board change | SEC |
| 4 · Change in ownership | Aug 17, 2021 | Insider trade | SEC |
This page holds 200 of 243 filings. Open Filings
Cap table
Built by 6ix from Gain Therapeutics, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 44,525,347
- Fully diluted
- 44,525,347
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 44,525,347 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 44,525,347 |
| Sep 30, 2026 | 44,324,134 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dov Goldstein Other companies: BioAge Labs, Inc. (Chief Financial Officer · Since at least Sep 25, 2024); Coya Therapeutics, Inc. (Director · Since at least Dec 28, 2022); NeuBase Therapeutics Inc (Director · Jul 12, 2019 – Sep 9, 2022 · Past); Loxo Oncology Inc (CFO and Treasurer · Jul 31, 2014 – Apr 1, 2015 · Past); Esperion Therapeutics, Inc. (Director · Jun 25, 2013 – Jun 6, 2018 · Past); Durata Therapeutics Inc (Director · Jul 18, 2012 – Jul 24, 2012 · Past); ADMA Biologics Inc (Director · Feb 13, 2012 – Feb 28, 2020 · Past); Cempra Inc (Director · Feb 2, 2012 – Mar 7, 2017 · Past) | Independent Member · Since at least Mar 17, 2021 |
| Gwen Melincoff Other companies: Chemomab Therapeutics Ltd. (Board Director · Since at least Jun 1, 2026); Protalix BioTherapeutics, Inc. (de) (Director · Since at least Jan 1, 2020); Soleno Therapeutics, Inc. (Director · Apr 26, 2019 – May 25, 2023 · Past); Collegium Pharmaceutical, Inc. (Director · Aug 9, 2017 – May 16, 2024 · Past); Tobira Therapeutics Inc (Director · May 4, 2015 – Nov 1, 2016 · Past) | Independent Member · Since at least Mar 17, 2021 |
| Charles Evan Ballantyne Other companies: Agenus Inc. (CFO · Jun 17, 2015 – Jun 14, 2016 · Past); Theriva Biologics, Inc. (Chief Financial Officer · Feb 6, 2012 – Jan 8, 2015 · Past); Clinical Data Inc (EVP, CFO · Jun 14, 2007 – Apr 12, 2011 · Past) | Chief Financial Officer · Apr 10, 2023 – Apr 10, 2023 · Past |
| Claude Nicaise Other companies: Filana Therapeutics, Inc. (Independent Director, Chairman of the Board · Since at least Dec 6, 2023); Chemomab Therapeutics Ltd. (Board Director · Since at least Mar 16, 2021); Sarepta Therapeutics, Inc. (Director · Since at least Jun 2, 2015) | Independent Member · Since at least Mar 17, 2021 |
| Khalid Islam Other companies: Fennec Pharmaceuticals Inc. (Chairman · Since at least Sep 11, 2017); Processa Pharmaceuticals, Inc. (Director · Nov 3, 2020 – Mar 31, 2022 · Past); Immunomedics Inc (Director · Mar 13, 2017 – Oct 23, 2020 · Past) | Chairman · Since at least Mar 17, 2021 |
| Eric I Richman Other companies: NeuBase Therapeutics Inc (Director · Jul 12, 2019 – Sep 9, 2022 · Past); ADMA Biologics Inc (Director · Nov 9, 2017 – Feb 28, 2020 · Past) | Director · Since at least Mar 17, 2021 |
| Hans Peter Hasler Other companies: Minerva Neurosciences, Inc (Member · Since at least Dec 10, 2017); Patheon N.V. (Director · Jul 20, 2016 – Aug 29, 2017 · Past) | Director · Since at least Mar 17, 2021 |
| Gene Mack Other companies: SELLAS Life Sciences Group, Inc. (CFO and Treasurer · Apr 20, 2018 – Apr 20, 2018 · Past) | Chief Executive Officer · Since at least Apr 5, 2024 |
| Jeffrey Riley Other companies: Theriva Biologics, Inc. (Chief Executive Officer, Director · Mar 16, 2010 – Nov 30, 2016 · Past) | Independent Member · Since at least Mar 17, 2021 |
| Matthias Alder Other companies: Sucampo Pharmaceuticals Inc (EVP, Gen. Council & Sec. · Mar 4, 2015 – Jun 30, 2017 · Past) | Chief Executive Officer, Director · Dec 23, 2021 – Mar 26, 2024 · Past |
All 15 people
| Person | Seat |
|---|---|
| Apaar Jammu | Director, Investor Relations and Public Relations · Since at least Oct 8, 2026 |
| Gianluca Fuggetta | See Remark · Since at least Dec 12, 2022 |
| Investors:Gain Therapeutics | Inc. Apaar Jammu Director, Investor Relations and Public · Since at least Oct 1, 2026 |
| Manolo Bellotto | President and General Manager · Mar 17, 2021 – Mar 17, 2021 · Past |
| Salvatore Calabrese | Chief Financial Officer · Mar 17, 2021 – Mar 23, 2023 · Past |
Log in to ask 6ix AI your own questions about Gain Therapeutics, Inc.